{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:43:41Z","timestamp":1777956221984,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2025-MS-337"],"award-info":[{"award-number":["2025-MS-337"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010018","name":"Doctoral Start-up Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2023-BSBA-206"],"award-info":[{"award-number":["2023-BSBA-206"]}],"id":[{"id":"10.13039\/501100010018","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Liaoning Provincial Department of Science and Technology","award":["2024JH2\/102600178"],"award-info":[{"award-number":["2024JH2\/102600178"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08053-w","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:32:28Z","timestamp":1774513948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Wei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanwen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xifeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"10500","key":"8053_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu J, Liu L, Parone P, Xie W, Sun C, Chen Z, et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet. 2025;406(10500):228\u201331.","journal-title":"Lancet"},{"issue":"7","key":"8053_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discovery. 2021;20(7):531\u201350.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"8053_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu Y, Zhao F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer. 2025;24(1):126.","journal-title":"Mol Cancer"},{"issue":"8","key":"8053_CR4","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1016\/j.apsb.2024.04.022","volume":"14","author":"D Xiong","year":"2024","unstructured":"Xiong D, Yu H, Sun ZJ. Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy. Acta Pharm Sin B. 2024;14(8):3416\u201331.","journal-title":"Acta Pharm Sin B"},{"key":"8053_CR5","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","volume":"77","author":"D Gumber","year":"2022","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941.","journal-title":"EBioMedicine"},{"issue":"6","key":"8053_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41577-022-00796-z","volume":"23","author":"BG Nixon","year":"2023","unstructured":"Nixon BG, Gao S, Wang X, Li MO. TGF\u03b2 control of immune responses in cancer: a holistic immuno-oncology perspective. Nat Rev Immunol. 2023;23(6):346\u201362.","journal-title":"Nat Rev Immunol"},{"key":"8053_CR7","doi-asserted-by":"crossref","unstructured":"Xue VW, Chung JY, C\u00f3rdoba CAG, Cheung AH, Kang W, Lam EW, et al. Transforming growth factor-\u03b2: a multifunctional regulator of cancer immunity. Cancers (Basel). 2020;12(11).","DOI":"10.3390\/cancers12113099"},{"key":"8053_CR8","doi-asserted-by":"publisher","first-page":"107101","DOI":"10.1016\/j.intimp.2020.107101","volume":"89","author":"H Zhao","year":"2020","unstructured":"Zhao H, Wei J, Sun J. Roles of TGF-\u03b2 signaling pathway in tumor microenvirionment and cancer therapy. Int Immunopharmacol. 2020;89:107101.","journal-title":"Int Immunopharmacol"},{"key":"8053_CR9","doi-asserted-by":"crossref","unstructured":"Morikawa M, Derynck R, Miyazono K. TGF-\u03b2 and the TGF-\u03b2 family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8(5).","DOI":"10.1101\/cshperspect.a021873"},{"issue":"2","key":"8053_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1248\/bpb.b21-00966","volume":"45","author":"T MaruYama","year":"2022","unstructured":"MaruYama T, Chen W, Shibata H. TGF-\u03b2 and Cancer Immunotherapy. Biol Pharm Bull. 2022;45(2):155\u201361.","journal-title":"Biol Pharm Bull"},{"issue":"19","key":"8053_CR11","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","volume":"186","author":"J Massagu\u00e9","year":"2023","unstructured":"Massagu\u00e9 J, Sheppard D. TGF-\u03b2 signaling in health and disease. Cell. 2023;186(19):4007\u201337.","journal-title":"Cell"},{"issue":"1","key":"8053_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.","journal-title":"J Exp Clin Cancer Res"},{"key":"8053_CR13","doi-asserted-by":"publisher","first-page":"106036","DOI":"10.1016\/j.phrs.2021.106036","volume":"175","author":"ZZ Zhang","year":"2022","unstructured":"Zhang ZZ, Wang T, Wang XF, Zhang YQ, Song SX, Ma CQ. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies. Pharmacol Res. 2022;175:106036.","journal-title":"Pharmacol Res"},{"key":"8053_CR14","doi-asserted-by":"crossref","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4).","DOI":"10.1172\/jci.insight.133977"},{"issue":"1","key":"8053_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, Cui H. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"8053_CR16","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li N, Rodriguez JL, Yin Y, Logun MT, Zhang L, Yu S, et al. Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma. Mol Ther. 2024;32(10):3522\u201338.","journal-title":"Mol Ther"},{"issue":"7","key":"8053_CR17","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, et al. Dominant-Negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018;26(7):1855\u201366.","journal-title":"Mol Ther"},{"key":"8053_CR18","doi-asserted-by":"crossref","unstructured":"Noh KE, Lee JH, Choi SY, Jung NC, Nam JH, Oh JS, et al. TGF-\u03b2\/IL-7 chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma. Int J Mol Sci. 2021;22(16).","DOI":"10.3390\/ijms22168706"},{"issue":"3","key":"8053_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41423-023-01120-y","volume":"21","author":"S Liang","year":"2024","unstructured":"Liang S, Zheng R, Zuo B, Li J, Wang Y, Han Y, et al. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. Cell Mol Immunol. 2024;21(3):213\u201326.","journal-title":"Cell Mol Immunol"},{"key":"8053_CR20","doi-asserted-by":"publisher","first-page":"155921","DOI":"10.1016\/j.phymed.2024.155921","volume":"133","author":"Y Guo","year":"2024","unstructured":"Guo Y, Xu J, Jia Y, Tian Y, Zhang Y, Zhang J, et al. Asiaticoside modulates human NK cell functional fate by mediating metabolic flexibility in the tumor microenvironment. Phytomedicine. 2024;133:155921.","journal-title":"Phytomedicine"},{"key":"8053_CR21","doi-asserted-by":"publisher","first-page":"106942","DOI":"10.1016\/j.phrs.2023.106942","volume":"197","author":"W Jiang","year":"2023","unstructured":"Jiang W, Gu G, Zhang Y, Song Y, Shi M, Wang G, et al. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression. Pharmacol Res. 2023;197:106942.","journal-title":"Pharmacol Res"},{"key":"8053_CR22","doi-asserted-by":"publisher","first-page":"112175","DOI":"10.1016\/j.intimp.2024.112175","volume":"134","author":"C Ye","year":"2024","unstructured":"Ye C, Yao Z, Wang Y, Zhang C. Asiaticoside promoted ferroptosis and suppressed immune escape in gastric cancer cells by downregulating the Wnt\/\u03b2-catenin pathway. Int Immunopharmacol. 2024;134:112175.","journal-title":"Int Immunopharmacol"},{"key":"8053_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms221910828","volume":"22","author":"V Pietrobon","year":"2021","unstructured":"Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-Cell Persistence. Int J Mol Sci. 2021;22:19.","journal-title":"Int J Mol Sci"},{"issue":"69","key":"8053_CR24","doi-asserted-by":"publisher","first-page":"eabi4613","DOI":"10.1126\/sciimmunol.abi4613","volume":"7","author":"JM Moreau","year":"2022","unstructured":"Moreau JM, Velegraki M, Bolyard C, Rosenblum MD, Li Z. Transforming growth factor-\u03b21 in regulatory T cell biology. Sci Immunol. 2022;7(69):eabi4613.","journal-title":"Sci Immunol"},{"issue":"1","key":"8053_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024;9(1):170.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"8053_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40259-022-00521-1","volume":"36","author":"NP Tschernia","year":"2022","unstructured":"Tschernia NP, Gulley JL. Tumor in the Crossfire: Inhibiting TGF-\u03b2 to Enhance Cancer Immunotherapy. BioDrugs. 2022;36(2):153\u201380.","journal-title":"BioDrugs"},{"issue":"1","key":"8053_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-025-00818-7","volume":"13","author":"L Wang","year":"2025","unstructured":"Wang L, Zhang Q, Wang X, Dong Z, Liu S, Wang Q, et al. Therapeutic landscape of ovarian cancer: recent advances and emerging therapies. Biomark Res. 2025;13(1):103.","journal-title":"Biomark Res"},{"issue":"5","key":"8053_CR28","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.immuni.2018.04.026","volume":"48","author":"B Bengsch","year":"2018","unstructured":"Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O\u2019Brien S, et al. Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity. 2018;48(5):1029\u2013e10455.","journal-title":"Immunity"},{"issue":"7709","key":"8053_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307\u201312.","journal-title":"Nature"},{"key":"8053_CR30","doi-asserted-by":"publisher","first-page":"656364","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance. Front Immunol. 2021;12:656364.","journal-title":"Front Immunol"},{"key":"8053_CR31","doi-asserted-by":"publisher","first-page":"104380","DOI":"10.1016\/j.ebiom.2022.104380","volume":"86","author":"AE Metropulos","year":"2022","unstructured":"Metropulos AE, Munshi HG, Principe DR. The difficulty in translating the preclinical success of combined TGF\u03b2 and immune checkpoint inhibition to clinical trial. EBioMedicine. 2022;86:104380.","journal-title":"EBioMedicine"},{"key":"8053_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s11658-020-00226-9","volume":"25","author":"J Zhao","year":"2020","unstructured":"Zhao J, Shi J, Shan Y, Yu M, Zhu X, Zhu Y, et al. Asiaticoside inhibits TGF-\u03b21-induced mesothelial-mesenchymal transition and oxidative stress via the Nrf2\/HO-1 signaling pathway in the human peritoneal mesothelial cell line HMrSV5. Cell Mol Biol Lett. 2020;25:33.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"8053_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08053-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08053-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08053-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:26:22Z","timestamp":1777944382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08053-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8053"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08053-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental protocols adhered to the ethical principles of the Declaration of Helsinki. This study was approved by the Institutional Review Board of Liaoning Cancer Hospital & Institute (Approval No. KY20251111), and written informed consent was obtained from all participants. Animal studies were approved by the Institutional Animal Care and Use Committee of Harbin Medical University Cancer Hospital (Approval No. KY2022-18).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"631"}}